Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3033 in Healthy Participants
NCT07456839Phase 1Active, not recruiting
- Sponsor
- Innovent Biologics
- Start
- Mar 2026
- Primary completion
- Sep 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IBI3033 (3 arms), sponsored by Innovent Biologics. Primary endpoint: Incidence of adverse events (AEs)/serious adverse events (SAEs) at Day 113. Started Mar 2026; status: active, not recruiting.
02
Drugs
IBI3033
Beyond the preview
Go deeper on NCT07456839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07456839.